A LinkedIn post from ThinkCyte describes engagement with researchers at Scripps Research around its AI-powered cell analysis platform VisionSort. The post highlights strong interest and discussions in areas such as flow cytometry, regenerative medicine, drug discovery, and AI in biology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also indicates that VisionSort will be available for hands-on demonstrations at Scripps Research throughout April, with an invitation for prospective users to book demo slots. For investors, this suggests ongoing efforts to drive academic and translational adoption, which could help validate the technology, broaden its user base, and support future commercialization and partnership opportunities.